Why Molecular Structure Matters

Structure is the identity

A peptide is defined by which amino acids it contains and in what order (its sequence), plus any changes made to it. Changing one position, the shape of the chain, or the chemical groups attached can alter how the molecule binds a receptor, how fast enzymes cut it, how long it lasts and how the immune system sees it. That is why a name is not enough and why exact identity needs a source.

What changes, and what it did

Each row is from a medicine label, which describes an approved product.

Note what the last row shows: a modest change kept the antidiuretic effect while reducing another effect. The structure change did not just make the molecule "stronger."

Left-handed and right-handed amino acids

Amino acids can exist in two mirror-image forms, written L and D. The leuprolide label's chemical name lists L-forms with one D-leucine. [4] Swapping a D-amino acid into a peptide is a recognized way to improve its stability against enzymes. [8] Other tools include cyclization, N-methylation and attaching lipid chains. [8][9] The same change can alter more than stability. FDA notes that ipamorelin contains unnatural amino acids, which adds to the complexity of characterizing the peptide. [10]

Fragments are not automatically the whole molecule

Teriparatide shows a fragment can keep a hormone's action. That does not mean every fragment does. Thymosin beta-4 is a 43-amino-acid peptide. [11] FDA's list of compounding substances names a thymosin beta-4 fragment (LKKTETQ), also known as TB-500, and says it has not found human exposure data for products containing it. [10] A 2012 analytical study found an acetylated 17-23 fragment, Ac-LKKTETQ, in a product called TB-500. [12] Research on the full 43-amino-acid molecule cannot simply be applied to a seven-amino-acid fragment. See TB-500 and thymosin beta-4.

Salt forms and impurities

The same peptide can be made as different salts. FDA says that semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs, and that it does not know whether they have the same chemical and pharmacologic properties. [13] Peptide products can also contain peptide-related impurities and aggregates, which FDA flags for several compounds as a source of immune-reaction risk. [10] See immunogenicity of peptide medicines.

Take-home points

• Structure is verified from a regulator, a label or a registry, not from a product page.
• A small change can mean a different medicine, with a different evidence base.
• When identity cannot be confirmed, the safest statement is that identity is uncertain; see research peptide naming and identity problems.

This page is education only and offers no manufacturing or synthesis detail.